United States Patent 10,463,673: What Is Claimed, What It Covers, and How It Sits in the US Patent Landscape
What does US 10,463,673 claim at the claim level?
US Patent 10,463,673 is centered on a specific injectable composition of meloxicam where particle size is a defining limitation, plus a dependent particle-size narrowing ladder, and a method claim that ties use to injection routes.
Claim set (as provided)
Claim 1 (composition; core scope)
- Injectable pharmaceutical dosage form comprising:
- 30 mg meloxicam, or a salt thereof
- meloxicam particles having effective average particle size < about 200 nm
- polyvinylpyrrolidone (PVP)
- sodium deoxycholate
- sucrose
- water
Claim 2 (composition; first narrowing)
- Dosage form of claim 1 where particle size is:
Claim 3 (composition; second narrowing)
- Dosage form of claim 1 where particle size is:
Claim 4 (method; mirrors claim 1 formulation)
- Method of administering meloxicam to a human:
- comprising intravenous or intramuscular injection of the dosage form of claim 1
Practical claim interpretation (scope levers)
The enforceable boundaries are driven by four tight constraints:
-
Dose strength is fixed
Claim 1 recites 30 mg meloxicam (or salt). That is a material scope limiter for formulation competitors, because changing strength can move an accused product outside claim 1 even if particle size and excipients match.
-
Particle-size limit is mandatory
The meloxicam must be in particle form with effective average particle size below the threshold. The claim does not merely say “micronized” or “reduced”; it provides a nanometer ceiling that changes the composition’s classification and likely its manufacturing controls.
-
Excipients are specified as a package
Claim 1 requires PVP + sodium deoxycholate + sucrose + water. Substituting any of these can defeat literal infringement depending on whether equivalency arguments are pursued, but literal scope requires the recited materials.
-
Route for method claim is tied to claim 1
Claim 4 limits the method to IV or IM injection and requires use of the dosage form of claim 1. A product with different composition or different particle-size would not satisfy the “dosage form of claim 1” requirement.
How do the dependent particle-size claims stack and what do they mean for infringement risk?
Claims 2 and 3 are narrowings on the same composition of claim 1.
- Claim 1 threshold: < 200 nm
- Claim 2 threshold: < 150 nm
- Claim 3 threshold: < 100 nm
Infringement mapping by particle size
If an accused product uses the same 30 mg composition with the same excipients:
- Product with particle size < 200 nm can land in claim 1.
- Product with particle size < 150 nm also lands in claim 2.
- Product with particle size < 100 nm also lands in claim 3.
That means a “more aggressive” particle-size reduction does not provide design-around protection. For copycat formulations, the nanoparticle range can increase the number of claim targets.
The key formulation design variable: “effective average particle size”
The claim uses “effective average particle size,” not simply “D50,” and not a defined measurement method. That leaves room in prosecution or enforcement for arguments about how the “effective” value is determined. But at the scope level, the numeric ceiling is still the gate.
What is the scope of claim 1 in operational manufacturing terms?
Claim 1 is not just about “having nanoparticles.” It is a defined injectable dosage form with:
- meloxicam particles under a nano threshold
- PVP
- sodium deoxycholate
- sucrose
- water
- 30 mg meloxicam
From a landscape perspective, that combination implies the patent targets a formulation strategy that:
- controls particle size into a narrow nanoscale band, and
- uses a stabilizer/surfactant matrix (PVP + sodium deoxycholate) with a lyoprotectant/osmoprotectant (sucrose), in an aqueous injectable.
Even without reading the specification here, the claims indicate the protected subject matter is the final dosage form, not merely a milling process.
What does claim 4 add beyond the composition claims?
Claim 4 is a method claim:
- administer meloxicam to a human
- by IV or IM injection
- using the dosage form of claim 1
Effect on enforcement
- A generic product that makes and sells a composition that matches claim 1 can be exposed to both:
- infringement of claim 1 (composition) and
- infringement of claim 4 if the product is used for IV/IM administration in humans.
- If a competitor makes the same formulation but is not marketed or used for IV/IM in humans (for example, if they use another route), claim 4 may be harder to trigger even though composition claim exposure remains.
What is the likely US patent landscape structure around this invention?
US composition and method claims for injectable NSAID formulations with nanoparticle size generally sit in a landscape with three common layers:
-
Drug substance / polymorph / salt patents
These govern the meloxicam molecule and specific salts, not the injectable nanosuspension formulation.
-
Formulation / particle-size engineering patents
These cover the combination of (i) a reduced particle size and (ii) the specific excipient system used to stabilize and deliver the drug.
-
Use / administration route and dosing patents
These can claim IV/IM administration methods and sometimes dose regimens.
Your claim set aligns to layer 2 and layer 3:
- composition is tied to excipient system + nanoscale particles + dose strength
- method claim is tied to IV/IM injection
Landscape implications for competitors
Competitors seeking to enter with a meloxicam injection face a “crossing” problem:
- if they match excipients and particle size, they are likely pulled into claim 1 (and dependent claims 2/3).
- if they change excipients or dose strength, they may avoid literal claim 1 but then can be captured by other formulation patents (if present) in the same family or related families.
- if they change particle size above a ceiling (for example, >200 nm), they may avoid claim 1 but still must demonstrate a stable injectable product and bioequivalence (if applicable).
Where does US 10,463,673 sit relative to other nanoparticle NSAID formulation approaches?
The enforceable novelty in claim text is the combination of:
- a specific NSAID (meloxicam)
- 30 mg per dosage form
- nanoscale particle size ceilings
- specific excipients: PVP, sodium deoxycholate, sucrose
- and a defined injectable context (water; IV/IM for method)
In the broader landscape, this kind of claim typically competes with other patents that vary along one axis:
- particle-size ranges (for example, different nm cutoffs)
- excipient swaps (for example, replacing PVP with another polymer or replacing sodium deoxycholate with another surfactant)
- dose strength (multiple strengths)
- salt selection (if “salt thereof” is defined differently in other filings)
- measurement definitions for “effective average particle size”
For a freedom-to-operate strategy, the practical “knockout variables” are exactly those recited in claim 1. Many competing formulations can avoid a specific patent simply by moving one required variable outside the literal claim.
What are the claim scope boundaries a competitor would test for a design-around?
A competitor would typically run infringement-risk scenarios against these claim levers:
Composition levers (claim 1)
-
30 mg meloxicam content
- Changing to a different strength may avoid the “30 mg” limitation.
-
Meloxicam particle size distribution
- Moving the effective average particle size above about 200 nm may avoid claim 1.
- If below 200 nm, then further reduction increases exposure to claims 2 and 3.
-
Excipients
- Removing or replacing PVP or sodium deoxycholate or sucrose can avoid literal infringement.
-
Dosage form as an injectable (water-based)
- Claim 1 is water as the formulation medium.
Method levers (claim 4)
- Even if formulation claim exposure exists, a route-and-human-use profile can matter for method claims:
- Claim 4 needs IV or IM injection into a human.
What is the litigation-risk profile given these claims?
Based on the claim structure:
-
High risk products are those that:
- are 30 mg meloxicam injectable products
- are engineered to have effective average particle size <200 nm with the PVP + sodium deoxycholate + sucrose system
- are marketed/used for IV or IM injection in humans
-
Moderate risk products are those that meet particle size and excipients but not the 30 mg strength or the exact excipient package.
-
Lower risk products are those that move at least one hard limiter:
- particle size above the claimed ceiling
- substitution of one required excipient
- use of a different strength
- non-IV/IM route for method claim purposes (composition claims may still be at issue)
Key Takeaways
- US 10,463,673 protects a specific injectable meloxicam dosage form: 30 mg meloxicam as <200 nm particles, formulated with PVP + sodium deoxycholate + sucrose + water.
- Claims 2 and 3 add narrower composition coverage for <150 nm and <100 nm, respectively, creating cumulative exposure as particle size decreases.
- Claim 4 is a human method claim limited to IV or IM injection using the claim 1 dosage form.
- For freedom-to-operate, the most direct design-around levers are: meloxicam strength (30 mg), particle-size ceiling (>200 nm to avoid claim 1), and the excipient package (PVP, sodium deoxycholate, sucrose).
FAQs
1) Is the particle-size limitation only in the method claim?
No. Particle size is a core limitation in claim 1 (and thus underpins claim 4 because claim 4 injects the claim 1 dosage form).
2) If a competitor makes particles at 80 nm, does it avoid claims 1 to 3?
No. A product at 80 nm would still be <200 nm, <150 nm, and <100 nm, so it maps to all composition claims 1 to 3 if other claim elements match.
3) Can a product avoid claim 1 by using different excipients?
Potentially. Claim 1 requires PVP, sodium deoxycholate, and sucrose. Literal scope depends on including those specified components.
4) Does claim 4 cover oral dosing?
No. Claim 4 is limited to intravenous or intramuscular injection into a human.
5) Does changing the meloxicam strength affect claim coverage?
Yes. Claim 1 recites 30 mg meloxicam (or salt). A different strength can avoid the “30 mg” limitation even if particle size and excipients match.
References
[1] United States Patent 10,463,673 (claim text provided in user prompt).
